Clinical trials
Phase 4 Leukemia, Myeloid, Acute trials in China
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
13 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2010 | 2 |
| 2013 | 2 |
| 2015 | 1 |
| 2016 | 1 |
| 2017 | 2 |
| 2019 | 1 |
| 2022 | 2 |
| 2024 | 1 |
| 2025 | 1 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Unknown status | 6 |
| Active, not recruiting | 2 |
| Completed | 2 |
| Recruiting | 2 |
| Not yet recruiting | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Novartis Pharmaceuticals | 2 |
| Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine | 2 |
| AbbVie | 1 |
| Changhai Hospital | 1 |
| Fujian Medical University Union Hospital | 1 |
| He Huang | 1 |
| Nanfang Hospital, Southern Medical University | 1 |
| Peking University People's Hospital | 1 |
| Shenzhen Second People's Hospital | 1 |
| The First Hospital of Jilin University | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Leukemia, Myeloid, Acute | 13 |
| Bronchiolitis Obliterans Syndrome | 1 |
| Graft vs Host Disease | 1 |
| Hepatoblastoma | 1 |
| Lymphoma | 1 |
| Myelodysplastic Syndromes | 1 |
| Neuroblastoma | 1 |
| Polycythemia Vera | 1 |
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 |
| Primary Myelofibrosis | 1 |
Trials
Showing 1 to 13 of 13. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.